MYRIAD GENETICS, INC. (MYGN) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 120.70M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 638.90M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | $120.70M | (m) | (m) | $638.90M | (m) |
| 2026-03-31 | (m) | (m) | (m) | $120.30M | (m) | (m) | $673.70M | (m) |
| 2025-12-31 | (m) | (m) | (m) | $119.90M | (m) | (m) | $706.60M | (m) |
| 2025-09-30 | (m) | (m) | (m) | $119.50M | (m) | (m) | $728.10M | (m) |
| 2025-06-30 | (m) | (m) | $59.40M | $0.00 | (m) | (m) | $677.30M | (m) |
| 2025-03-31 | (m) | (m) | (m) | $59.30M | (m) | (m) | $1.01B | (m) |
| 2024-12-31 | (m) | (m) | (m) | $39.60M | (m) | $102.40M | $1.03B | (m) |
| 2024-09-30 | (m) | (m) | (m) | $39.00M | (m) | $99.90M | $1.08B | (m) |
| 2024-06-30 | (m) | (m) | (m) | $38.80M | (m) | $97.30M | $1.09B | (m) |
| 2024-03-31 | (m) | (m) | (m) | $38.70M | (m) | $104.30M | $1.11B | (m) |
| 2023-12-31 | (m) | (m) | (m) | $38.50M | (m) | $140.90M | $1.15B | (m) |
| 2023-09-30 | (m) | (m) | (m) | $38.50M | (m) | $86.30M | $1.15B | (m) |
| 2023-06-30 | (m) | (m) | (m) | $38.40M | (m) | $121.60M | $1.19B | (m) |
| 2022-12-31 | (m) | (m) | (m) | $0.00 | (m) | $114.90M | $1.20B | (m) |
| 2021-12-31 | (m) | (m) | (m) | $0.00 | (m) | $339.80M | $1.32B | (m) |
| 2021-09-30 | (m) | (m) | (m) | $0.00 | (m) | $366.10M | $1.34B | (m) |
| 2021-06-30 | (m) | (m) | $104.10M | $0.00 | (m) | $164.40M | $1.36B | (m) |
| 2020-12-31 | (m) | (m) | $0.00 | $224.80M | (m) | $150.70M | $1.42B | (m) |
| 2020-06-30 | (m) | (m) | (m) | $224.40M | (m) | $217.80M | $1.40B | (m) |
| 2020-03-31 | (m) | (m) | (m) | $225.20M | (m) | $181.50M | $1.45B | (m) |
| 2019-12-31 | (m) | (m) | (m) | $225.10M | (m) | $141.60M | $1.58B | (m) |
| 2019-09-30 | (m) | (m) | (m) | $225.00M | (m) | $142.60M | $1.59B | (m) |
| 2019-06-30 | (m) | (m) | (m) | $233.50M | (m) | $136.90M | $1.56B | (m) |
| 2019-03-31 | (m) | (m) | (m) | $263.40M | (m) | $149.70M | $1.56B | (m) |
| 2018-12-31 | (m) | (m) | (m) | $273.30M | (m) | $165.40M | $1.56B | (m) |
| 2018-09-30 | (m) | (m) | (m) | $258.00M | (m) | $167.50M | $1.57B | (m) |
| 2018-06-30 | (m) | (m) | (m) | $9.30M | (m) | $180.60M | $1.17B | (m) |
| 2018-03-31 | (m) | (m) | (m) | $69.30M | (m) | $157.30M | $1.22B | (m) |
| 2017-12-31 | (m) | (m) | (m) | $43.20M | (m) | $143.50M | $1.23B | (m) |
| 2017-06-30 | (m) | (m) | (m) | $99.10M | (m) | $150.70M | $1.22B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |